Premature ovarian insufficiency: pathogenesis and therapeutic potential of mesenchymal stem cell

Akimasa Takahashi, Abdelrahman Yousif, Linda Hong, IIana I. Chefetz

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Primary ovarian insufficiency (POI) is defined as a reduction in ovarian function before the expected age of menopause. POI is known to increase the risk of cardiovascular disorders, osteoporosis, cognitive decline, and mood disorders, resulting in a reduced quality of life. Appropriate hormone replacement for premenopausal women decreases these adverse health risks and improves quality of life for women with POI, but does not prolong life expectancy. The potential etiologies of POI include chromosomal abnormalities and genetic mutations, autoimmune factors, and iatrogenic causes, including surgery, chemotherapy, and radiation therapy. A major association is suggested to exist between reproductive longevity and the DNA damage pathway response genes. DNA damage and repair in ovarian granulosa cells is strongly associated with POI. Depletion of oocytes with damaged DNA occurs through different cell death mechanisms, such as apoptosis, autophagy, and necroptosis, mediated by the phosphatase and tensin homolog (PTEN)/phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/forkhead transcription factors 3 (FOXO3) pathway. Mesenchymal stem cells (MSCs) are characterized by the ability of self-renewal and differentiation and play an important role in the regeneration of injured tissues. Transplantation of MSCs has been shown to functionally restore ovarian reserve in a POI mouse model. Recent advances in stem cell therapy are likely to be translated to new therapeutic options bringing new hope to patients with POI. The aim of this review is to summarize the pathogenic mechanisms that involve cell death and DNA damage and repair pathways and to discuss the stem cell–based therapies as potential therapeutic options for this gynecologic pathology.

Original languageEnglish (US)
Pages (from-to)637-650
Number of pages14
JournalJournal of Molecular Medicine
Issue number5
StatePublished - May 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.


  • Cell death
  • DNA repair
  • Hormone replacement therapy
  • Menopause
  • Mesenchymal stem cells
  • Ovary
  • Premature ovarian insufficiency

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review


Dive into the research topics of 'Premature ovarian insufficiency: pathogenesis and therapeutic potential of mesenchymal stem cell'. Together they form a unique fingerprint.

Cite this